65,437 trials
Bipolar Disorder
Primary: Change From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score — -12.6; -14.3; -6.8 units on a scale — p=<0.001
Measles · Mumps · Rubella
Primary: Number of Participants With Varicella Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Antibody Titer ≥ 5 gpELISA Units — 198; 299; 253; 303 Participants
Asthma
Primary: Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52 — 0.20; 0.09 Liters — p=<0.001
Breast Neoplasm
Primary: Number of Participants Who Had a Tumor Response, According to Standard RECIST (Response Evaluation Criteria in Solid Tumors) Criteria — 2; 13; 11 Participants
Advanced Cancer Relapsed · Advanced Cancer Refractory
Primary: Change From Baseline in QTcF at 0.5 Hours — 1.78; -1.22 milliseconds
Chemotherapy-Induced Nausea and Vomiting (CINV)
Primary: A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin). — 795; 820 Participants
Attention Deficit Hyperactivity Disorder · Oppositional Defiant Disorder
Primary: Swanson, Nolan and Pelham Rating Scale Revised (SNAP-IV) Oppositional Defiant Disorder: (ODD) Score — 8.6; 9.0; 12.0 units on a scale — p=<.001
Diabetes Mellitus · Coronary Artery Disease
Primary: Inhibition of Platelet Aggregation (IPA) 4 Hours After Loading Dose Assessed by Accumetrics VerifyNow™ P2Y12 Assay — 9.4; 9.3; 89.3; 27.7 percent inhibition — p=<0.0001
Osteoporosis
Primary: Part 1: The Total Urinary Excretion of Alendronate With Alendronate/Vitamin D Combination Tablet Relative to Alendronate Tablet — 197.5; 191.9 micrograms (μg)
Diphtheria · Tetanus · Haemophilus Infection
Primary: Percentage of Participants With 4-fold Rises in Levels of Pentacel™ Vaccine Antibody Titers Post-dose 3 When Given at Different Times or Concurrently With a Pneumococcal…
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
Neoplasms, Glandular and Epithelial · Diphtheria · Tetanus
Primary: Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 7 (4 Weeks Postdose 3) — 1151.3; 1244.9 milliMerck units/mL — p=<0.001
Carcinoma, Renal Cell
Primary: Number of Subjects With Objective Response — 12; 12; 1; 0 participants
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -49.45; -34.43 percent change — p=<0.01
Overactive Bladder · Urinary Incontinence
Primary: Change in Number of Urinary Urge Incontinence Episodes — 32.5; 30.3; 27.8; 28.3 episodes